MétaCan
Menu
← Back to cohort

Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P2.144)

2016· article· en· W2604913632 on OpenAlexaff
J. Theodore Phillips, Amit Bar‐Or, Ralf Gold, Gavin Giovannoni, Robert J. Fox, James Potts, Teesta Soman, Jing L. Marantz

Bibliographic record

VenueNeurology · 2016
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsMontreal Neurological Institute and Hospital
Fundersnot available
KeywordsDimethyl fumarateRelapsing remittingMultiple sclerosisMedicineImmunology

Abstract

fetched live from OpenAlex

Objective: Assess the effect of delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) on multi-component composite endpoints in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) from DEFINE/CONFIRM. Background: DMF significantly reduced confirmed disability progression (CDP) as measured by Expanded Disability Status Scale (EDSS) in an integrated analysis of DEFINE/CONFIRM of patients newly diagnosed with RRMS. A composite outcome, using multiple neuroperformance components, can potentially enhance the measurement of CDP. Methods: Eligible patients were randomized to receive DMF 240 mg twice (BID) or thrice daily, placebo, or glatiramer acetate (CONFIRM only) for up to 2 years. Assessments were administered at baseline and 12-week intervals thereafter. Composite-CDP was defined by the first occurrence of worsening from baseline of any one of the following: ≥1.0- or ≥1.5-point increase in EDSS score (>0 or 0, respectively); or ≥20[percnt] on timed 25-foot walk (T25FW), 9-hole peg test (9HPT), or Paced Auditory Serial Addition Test (PASAT); or ≥10-letter on Visual Function Test (VFT), confirmed at 12- and 24-weeks. Statistical comparisons were based on a Cox proportional hazards model adjusted for baseline covariates. DMF BID (approved dosage) results are reported. “Newly diagnosed” was defined as diagnosis within 1 year prior to study entry and treatment-naïve or previously treated with corticosteroids alone. Results: Newly diagnosed population included 221 DMF and 223 placebo patients. Compared with placebo at Year 2, DMF significantly reduced the risk for 12-week composite-CDP (hazard ratio, 95[percnt] confidence interval: 0.68, 0.49-0.94) and 24-week composite-CDP (0.56, 0.37-0.84) as measured by worsening of any of the disability outcomes (EDSS, T25FW, 9HPT, PASAT, or VFT); this represented 32[percnt] (P=0.0198) and 44[percnt] (P=0.0053) reductions vs placebo, respectively. Additional outcomes will also be presented. Conclusions: DMF demonstrated significant reductions compared with placebo on a composite measure of disability progression in newly diagnosed RRMS patients. Study supported by: Biogen.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.070
GPT teacher head0.320
Teacher spread0.250 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeurology→Same topicMultiple Sclerosis Research Studies→French-language works237,207→